Sandy Allerheiligen Email Address

Senior Vice President Strategic Consulting, Health Economics, and Education

Certara is a leading decision support technology and consulting organization committed to optimizing drug development and improving health outcomes. Certara's solutions, which span drug discovery through patient care, use the most scientifically-advanced modeling and simulation technologies and regulatory strategies to increase the probability of regulatory and commercial success. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies.

Sandy Allerheiligen, PhD joined Merck in 2010 as Vice President of Modeling and Simulation, and was named Vice President of PPDM: Quantitative Pharmacology & Pharmacometrics in 2013. Her team has been instrumental in expanding Model Informed Drug Development. In 2015, she became Vice President of Predictive and Economic Modeling using quantitative approaches to inform discovery to clinical trials to patient access. Prior to joining Merck, she held positions at Eli Lilly & Company including Global Senior Director Pharmacokinetics, Pharmacodynamics (PK/PD) & Trial Simulation, Senior Director Drug Disposition, and Distinguished Fellow & Chief Scientific Officer of Quantitative Pharmacology. Her research focuses application of mathematical methods to enable quantitative decisions for nonclinical, clinical development, and patient access. She has applied modeling and simulation approaches to oncolytic and endocrine agents. Her recent work has focused on the integration of experimental and real world data to enable development of drug disease models to inform decisions through the utilization of quantitative and systems pharmacology and other modeling approaches. Dr. Allerheiligen received her doctorate in Pharmaceutics from the University of Texas, Austin. She completed her postdoctoral fellowship in Gastroenterology and served as a clinical assistant professor of Clinical Pharmacology at The University of Texas Health Science Center at San Antonio. Through her involvement in American Association of Pharmaceutical Scientists, American Association of Clinical Pharmacology and Therapeutics, International Society of Pharmacometrics, and NIH Working Groups, she has worked to expand the use of Modeling and Simulation and Quantitative & Systems Pharmacology methodologies in academia, regulatory agencies, and across the industry. She is a Fellow of the American Association of Pharmaceutical Sciences and frequently lectures on modeling and simulation topics.